Nektar Therapeutics (0UNL.L)
USD 0.84
(0.63%)
USD 0.84
(0.63%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -276.05 Million USD | 25.03% |
| 2022 | -368.19 Million USD | 29.71% |
| 2021 | -523.83 Million USD | -17.86% |
| 2020 | -444.44 Million USD | -0.86% |
| 2019 | -440.66 Million USD | -164.68% |
| 2018 | 681.31 Million USD | 804.62% |
| 2017 | -96.69 Million USD | 37.02% |
| 2016 | -153.52 Million USD | -89.12% |
| 2015 | -81.17 Million USD | -50.56% |
| 2014 | -53.91 Million USD | 66.72% |
| 2013 | -162.01 Million USD | 5.73% |
| 2012 | -171.85 Million USD | -28.27% |
| 2011 | -133.97 Million USD | -253.15% |
| 2010 | -37.93 Million USD | 62.99% |
| 2009 | -102.51 Million USD | -198.58% |
| 2008 | -34.33 Million USD | -4.81% |
| 2007 | -32.76 Million USD | 78.83% |
| 2006 | -154.76 Million USD | 16.4% |
| 2005 | -185.11 Million USD | -81.68% |
| 2004 | -101.88 Million USD | -118.26% |
| 2003 | -46.68 Million USD | 56.56% |
| 2002 | -107.46 Million USD | 57.01% |
| 2001 | -250 Million USD | -156.67% |
| 2000 | -97.4 Million USD | -153.34% |
| 1999 | -38.44 Million USD | -109.46% |
| 1998 | -18.35 Million USD | -83.87% |
| 1997 | -9.98 Million USD | 0.17% |
| 1996 | -10 Million USD | -29.87% |
| 1995 | -7.7 Million USD | -45.28% |
| 1994 | -5.3 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -52.36 Million USD | -42.28% |
| 2024 Q1 | -36.8 Million USD | 12.54% |
| 2023 FY | -276.05 Million USD | 25.03% |
| 2023 Q1 | -137.01 Million USD | -129.56% |
| 2023 Q2 | -51.12 Million USD | 62.69% |
| 2023 Q3 | -45.83 Million USD | 10.34% |
| 2023 Q4 | -42.07 Million USD | 8.2% |
| 2022 Q2 | -159.06 Million USD | -75.97% |
| 2022 Q1 | -90.39 Million USD | 37.94% |
| 2022 FY | -368.19 Million USD | 29.71% |
| 2022 Q4 | -59.68 Million USD | -1.08% |
| 2022 Q3 | -59.04 Million USD | 62.88% |
| 2021 Q1 | -122.96 Million USD | -4.92% |
| 2021 Q2 | -125.51 Million USD | -2.08% |
| 2021 FY | -523.83 Million USD | -17.86% |
| 2021 Q3 | -129.7 Million USD | -3.34% |
| 2021 Q4 | -145.64 Million USD | -12.29% |
| 2020 Q3 | -108.58 Million USD | -35.73% |
| 2020 Q2 | -80 Million USD | 42.3% |
| 2020 FY | -444.44 Million USD | -0.86% |
| 2020 Q4 | -117.2 Million USD | -7.94% |
| 2020 Q1 | -138.65 Million USD | -23.61% |
| 2019 Q3 | -98.8 Million USD | 10.1% |
| 2019 Q1 | -118.51 Million USD | -20.67% |
| 2019 FY | -440.66 Million USD | -164.68% |
| 2019 Q4 | -112.16 Million USD | -13.52% |
| 2019 Q2 | -109.9 Million USD | 7.26% |
| 2018 Q4 | -98.21 Million USD | -2.15% |
| 2018 Q3 | -96.14 Million USD | -109.9% |
| 2018 FY | 681.31 Million USD | 804.62% |
| 2018 Q2 | 971.46 Million USD | 1114.13% |
| 2018 Q1 | -95.79 Million USD | -183.19% |
| 2017 Q3 | 60.87 Million USD | 201.67% |
| 2017 Q1 | -63.86 Million USD | -51.34% |
| 2017 Q2 | -59.87 Million USD | 6.26% |
| 2017 Q4 | -33.82 Million USD | -155.57% |
| 2017 FY | -96.69 Million USD | 37.02% |
| 2016 Q4 | -42.19 Million USD | 2.37% |
| 2016 FY | -153.52 Million USD | -89.12% |
| 2016 Q2 | -48.6 Million USD | -149.27% |
| 2016 Q1 | -19.49 Million USD | 63.98% |
| 2016 Q3 | -43.22 Million USD | 11.07% |
| 2015 Q3 | -8.2 Million USD | 84.42% |
| 2015 FY | -81.17 Million USD | -50.56% |
| 2015 Q2 | -52.65 Million USD | -255.7% |
| 2015 Q1 | 33.82 Million USD | 174.03% |
| 2015 Q4 | -54.13 Million USD | -559.97% |
| 2014 Q1 | -46.2 Million USD | 3.06% |
| 2014 Q2 | -32.63 Million USD | 29.36% |
| 2014 Q3 | 70.6 Million USD | 316.33% |
| 2014 Q4 | -45.68 Million USD | -164.7% |
| 2014 FY | -53.91 Million USD | 66.72% |
| 2013 Q1 | -55.06 Million USD | -4.04% |
| 2013 FY | -162.01 Million USD | 5.73% |
| 2013 Q4 | -47.65 Million USD | -188.09% |
| 2013 Q3 | -16.54 Million USD | 61.3% |
| 2013 Q2 | -42.74 Million USD | 22.37% |
| 2012 Q3 | -43.54 Million USD | -27.01% |
| 2012 Q4 | -52.92 Million USD | -21.54% |
| 2012 Q1 | -41.09 Million USD | -9.61% |
| 2012 Q2 | -34.28 Million USD | 16.58% |
| 2012 FY | -171.85 Million USD | -28.27% |
| 2011 Q2 | -36.38 Million USD | -0.96% |
| 2011 FY | -133.97 Million USD | -253.15% |
| 2011 Q4 | -37.49 Million USD | -55.79% |
| 2011 Q3 | -24.06 Million USD | 33.84% |
| 2011 Q1 | -36.03 Million USD | -59.58% |
| 2010 Q4 | -22.58 Million USD | -159.21% |
| 2010 Q1 | -6.13 Million USD | 20.14% |
| 2010 FY | -37.93 Million USD | 62.99% |
| 2010 Q2 | -517 Thousand USD | 91.57% |
| 2010 Q3 | -8.71 Million USD | -1584.91% |
| 2009 Q1 | -31.8 Million USD | -141.43% |
| 2009 Q4 | -7.67 Million USD | 75.21% |
| 2009 Q3 | -30.96 Million USD | 3.44% |
| 2009 FY | -102.51 Million USD | -198.58% |
| 2009 Q2 | -32.06 Million USD | -0.82% |
| 2008 Q1 | -40.7 Million USD | -204.26% |
| 2008 FY | -34.33 Million USD | -4.81% |
| 2008 Q4 | 76.78 Million USD | 307.31% |
| 2008 Q3 | -37.03 Million USD | -10.98% |
| 2008 Q2 | -33.37 Million USD | 18.01% |
| 2007 Q1 | -25.67 Million USD | 33.93% |
| 2007 FY | -32.76 Million USD | 78.83% |
| 2007 Q4 | 39.04 Million USD | 309.68% |
| 2007 Q3 | -18.62 Million USD | 32.32% |
| 2007 Q2 | -27.51 Million USD | -7.16% |
| 2006 FY | -154.76 Million USD | 16.4% |
| 2006 Q1 | -33.47 Million USD | 69.08% |
| 2006 Q2 | -62.83 Million USD | -87.72% |
| 2006 Q4 | -38.85 Million USD | -98.2% |
| 2006 Q3 | -19.6 Million USD | 68.8% |
| 2005 FY | -185.11 Million USD | -81.68% |
| 2005 Q4 | -108.23 Million USD | -354.88% |
| 2005 Q2 | -26.91 Million USD | -2.85% |
| 2005 Q1 | -26.16 Million USD | -35.78% |
| 2005 Q3 | -23.79 Million USD | 11.58% |
| 2004 Q2 | -22.16 Million USD | 44.59% |
| 2004 Q3 | -20.45 Million USD | 7.72% |
| 2004 FY | -101.88 Million USD | -118.26% |
| 2004 Q4 | -19.27 Million USD | 5.78% |
| 2004 Q1 | -40 Million USD | -1238.95% |
| 2003 Q3 | -17.2 Million USD | -31.96% |
| 2003 Q2 | -13.03 Million USD | 34.64% |
| 2003 FY | -46.68 Million USD | 56.56% |
| 2003 Q4 | 3.51 Million USD | 120.41% |
| 2003 Q1 | -19.94 Million USD | 35.8% |
| 2002 FY | -107.46 Million USD | 57.01% |
| 2002 Q4 | -31.07 Million USD | -17.17% |
| 2002 Q3 | -26.52 Million USD | -6.87% |
| 2002 Q2 | -24.81 Million USD | 0.95% |
| 2002 Q1 | -25.05 Million USD | 30.88% |
| 2001 Q3 | -26.92 Million USD | 74.55% |
| 2001 Q1 | -81.04 Million USD | -104.6% |
| 2001 FY | -250 Million USD | -156.67% |
| 2001 Q2 | -105.79 Million USD | -30.54% |
| 2001 Q4 | -36.25 Million USD | -34.66% |
| 2000 Q1 | -28.83 Million USD | -42.92% |
| 2000 FY | -97.4 Million USD | -153.34% |
| 2000 Q3 | -13.21 Million USD | 16.08% |
| 2000 Q4 | -39.6 Million USD | -199.73% |
| 2000 Q2 | -15.74 Million USD | 45.38% |
| 1999 Q4 | -20.17 Million USD | -186.36% |
| 1999 Q3 | -7.04 Million USD | -17.3% |
| 1999 FY | -38.44 Million USD | -109.46% |
| 1999 Q2 | -6 Million USD | -14.99% |
| 1999 Q1 | -5.22 Million USD | 17.29% |
| 1998 Q4 | -6.31 Million USD | -25.25% |
| 1998 Q3 | -5.04 Million USD | -76.91% |
| 1998 Q2 | -2.85 Million USD | 31.31% |
| 1998 FY | -18.35 Million USD | -83.87% |
| 1998 Q1 | -4.14 Million USD | -38.76% |
| 1997 Q1 | -2.04 Million USD | 39.88% |
| 1997 Q3 | -2.65 Million USD | -15.36% |
| 1997 Q4 | -2.99 Million USD | -12.79% |
| 1997 FY | -9.98 Million USD | 0.17% |
| 1997 Q2 | -2.29 Million USD | -12.43% |
| 1996 Q3 | -2.3 Million USD | 8.0% |
| 1996 Q4 | -3.4 Million USD | -47.83% |
| 1996 Q1 | -1.9 Million USD | 17.39% |
| 1996 FY | -10 Million USD | -29.87% |
| 1996 Q2 | -2.5 Million USD | -31.58% |
| 1995 Q1 | -2.2 Million USD | 4.35% |
| 1995 Q2 | -1.6 Million USD | 27.27% |
| 1995 Q4 | -2.3 Million USD | -35.29% |
| 1995 Q3 | -1.7 Million USD | -6.25% |
| 1995 FY | -7.7 Million USD | -45.28% |
| 1994 Q1 | -1.1 Million USD | 0.0% |
| 1994 FY | -5.3 Million USD | 0.0% |
| 1994 Q4 | -2.3 Million USD | -155.56% |
| 1994 Q2 | -900 Thousand USD | 18.18% |
| 1994 Q3 | -900 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | 10.51% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -409.441% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -211.995% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 21.595% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 0.025% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -132.933% |
| Imunon, Inc. | -19.51 Million USD | -1314.585% |
| Dynavax Technologies Corporation | -6.38 Million USD | -4220.801% |
| Editas Medicine, Inc. | -153.21 Million USD | -80.171% |
| FibroGen, Inc. | -284.23 Million USD | 2.877% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 37.83% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -554.177% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 210.555% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 48.495% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 21076.9% |
| Verastem, Inc. | -87.36 Million USD | -215.973% |
| Zoetis Inc. | 2.34 Billion USD | 111.777% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 107.627% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | -7.069% |
| Homology Medicines, Inc. | -53.74 Million USD | -413.659% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -221.388% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -592.564% |
| Perrigo Company plc | -12.7 Million USD | -2073.669% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -31.928% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 96.803% |
| Illumina, Inc. | -1.16 Billion USD | 76.223% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 104.605% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 120.328% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -149.691% |
| Waters Corporation | 642.23 Million USD | 142.984% |
| Biogen Inc. | 1.16 Billion USD | 123.775% |
| Evolus, Inc. | -61.68 Million USD | -347.525% |
| Adicet Bio, Inc. | -142.65 Million USD | -93.509% |
| bluebird bio, Inc. | -211.91 Million USD | -30.269% |
| Geron Corporation | -184.12 Million USD | -49.927% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 37.294% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -82.114% |
| Myriad Genetics, Inc. | -112 Million USD | -146.479% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 42.631% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 134.998% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -518.914% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 264.667% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 106.982% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 122.263% |
| OPKO Health, Inc. | -188.86 Million USD | -46.167% |
| Exelixis, Inc. | 207.76 Million USD | 232.869% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 360.087% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -481.109% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -15.39% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 24.634% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 198.033% |
| Blueprint Medicines Corporation | -506.98 Million USD | 45.549% |
| Insmed Incorporated | -749.56 Million USD | 63.171% |
| TG Therapeutics, Inc. | 12.67 Million USD | 2278.472% |
| Incyte Corporation | 597.59 Million USD | 146.194% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 63.701% |